Creatine Monohydrate: What 500+ Trials Actually Show (And What the Marketing Gets Wrong)

Creatine monohydrate is one of the most heavily studied supplements in existence, with over 1,000 published human trials behind it, and the independent human evidence holds up: it reliably increases strength and power output when paired with resistance training, modestly improves specific cognitive domains like memory and processing speed (not overall "brainpower"), and does not damage healthy kidneys at standard doses. What does not hold up is most of the "next-generation" marketing — HCl, buffered, and nano forms have never beaten plain monohydrate in a properly controlled human trial, loading phases are a convenience, not a requirement, and the hair-loss scare traces back to a single 2009 rugby study that a 2025 randomized trial could not replicate. The dose that matters is 3-5 g/day of monohydrate, taken consistently, with genuine caution reserved for people who already have kidney disease or take nephrotoxic medications (Kabiri Naeini et al., BMC Nephrology 2025).

Table of contents

• Evidence summary
• What creatine monohydrate is
• All forms and types of creatine
• How creatine monohydrate works
• What works and what does not
• Benefits with evidence grades
• Risks and all side effects
• All interactions
• Who should avoid creatine monohydrate
• Dosage and how to take creatine monohydrate
• Infographics with full text versions
• Related research
• Frequently asked questions
• Sources and funding notes

Evidence summary

What creatine monohydrate is

Creatine is a naturally occurring nitrogenous organic compound synthesized in the human liver, kidneys, and pancreas from three amino acids: arginine, glycine, and methionine. It is also obtained from dietary sources, mainly red meat and fish, at roughly 1-2 g per kg of raw muscle tissue. About 95% of the body's creatine pool is stored in skeletal muscle, mostly as phosphocreatine, with the remaining 5% distributed in the brain, testes, and other tissues (Antonio et al. 2021 critical review).

Creatine monohydrate is simply creatine bound to one water molecule — the simplest, most-studied, and most stable commercial form. It is not a steroid, not a stimulant, and not classified as a banned substance by any major anti-doping authority; the World Anti-Doping Agency does not include creatine on its Prohibited List. The molecule's job in the body is narrow but important: it acts as a rapidly available phosphate donor that regenerates adenosine triphosphate (ATP), the cell's immediate energy currency, during short, high-intensity efforts.

Roughly two-thirds of a typical omnivorous adult's creatine pool comes from a combination of endogenous synthesis and dietary intake, with the muscle creatine pool sitting at somewhere between 60% and 80% of its theoretical maximum storage capacity in most people who do not supplement. That headroom — the gap between typical intake and maximum storage — is the entire premise behind supplementation: filling the tank raises the ceiling on how much phosphocreatine is available for rapid ATP regeneration (Antonio et al. 2021).

Vegetarians and vegans typically start with lower baseline muscle creatine stores than omnivores, since plant foods contain essentially no preformed creatine, which is one reason this population tends to show a larger relative response to supplementation (narrative review, Nutrients 2024).

All forms and grades

The supplement market sells at least a dozen creatine variants, most marketed as solving a problem monohydrate does not actually have (poor solubility, bloating, or "inferior absorption"). Independent head-to-head human trials tell a consistent story: nothing outperforms monohydrate, and several alternatives underperform it or add cost without added benefit.

How it works

Creatine's core mechanism is phosphagen-system energetics. Inside muscle cells, creatine is phosphorylated by creatine kinase into phosphocreatine (PCr), which acts as a rapid-fire phosphate reservoir. During short (roughly 1-10 second) maximal efforts — a heavy barbell rep, a sprint start, a vertical jump — ATP is consumed faster than oxidative or glycolytic pathways can regenerate it, and PCr donates a phosphate group to ADP to rapidly resynthesize ATP. Raising the muscle's total creatine and phosphocreatine pool via supplementation increases the size of this immediate energy buffer and appears to speed PCr resynthesis between efforts, which is the physiological basis for creatine's well-documented benefit in repeated short, high-intensity bouts (Antonio et al. 2021).

Beyond the phosphagen system, researchers have proposed several secondary mechanisms, with varying levels of human evidence:

• Cell volumization: Creatine draws water into muscle cells osmotically, which some researchers propose acts as an anabolic signal independent of the energetic effect; human evidence for this specific downstream signaling pathway is more mechanistic than directly demonstrated in vivo.
• Glycogen synthesis support: Some human trials show creatine loading combined with carbohydrate intake enhances muscle glycogen supercompensation, relevant to endurance and recovery contexts.
• Brain energy buffering: The brain uses roughly 20% of the body's resting energy expenditure, and neurons rely on the same phosphocreatine/ATP shuttle. This is the proposed mechanism behind cognitive effects under high energy-demand states such as sleep deprivation or acute stress, where brain phosphocreatine may become a limiting resource.
• Reduced oxidative and inflammatory markers: Some human trials report lower markers of exercise-induced muscle damage and oxidative stress with creatine supplementation, though this evidence is less consistent than the strength and power findings.

On absorption: oral creatine monohydrate is nearly completely absorbed from the gastrointestinal tract in humans, with bioavailability commonly cited near 100% for the monohydrate salt at standard doses, though rigorous modern pharmacokinetic head-to-head data across all "alternative" forms remains sparse (Antonio et al. 2021). Muscle uptake is influenced by insulin — co-ingesting creatine with carbohydrate or a carbohydrate-protein combination has been shown in human trials to enhance muscle creatine retention compared with creatine alone, likely via insulin-stimulated sodium-potassium ATPase activity that supports the creatine transporter (CreaT1).

What works and what does not

Muscle strength, power, and exercise performance

Strong — This is creatine's best-established use case by a wide margin. A 2024 meta-analysis of 23 randomized trials in adults under 50 found that adding creatine to a resistance training program increased upper-body strength by a weighted mean difference of 4.43 kg and lower-body strength by 11.35 kg compared with resistance training plus placebo (both p<0.001), with a trend toward larger gains in males than females (p=0.067) (Burke et al. 2024, Nutrients). This study declared no external funding.

A separate 2023 Bayesian meta-analysis focused specifically on muscle hypertrophy (not just strength) found a smaller but still positive pooled effect (0.11, 95% credible interval -0.02 to 0.25) across 10 RCTs, with the benefit more pronounced in younger versus older lifters — suggesting the hypertrophy signal, while real, is more modest than the strength signal (Burke, Piñero, Schoenfeld et al. 2023, Nutrients).

For power and repeated-sprint performance (relevant to team-sport and HIIT-style training), the effect is most consistent for efforts under roughly 30 seconds performed in repeated bouts with short rest — exactly the domain the phosphagen-energy mechanism predicts. Single, isolated sprints of very short duration and pure aerobic endurance events show little to no independent benefit, consistent with the mechanism: creatine buffers repeated short-duration anaerobic effort, not sustained aerobic output.

Cognitive function, sleep deprivation, and mental fatigue

Moderate, narrow — This is the most misunderstood claim in the current creatine marketing wave. A 2024 systematic review and meta-analysis of 16 RCTs (492 participants, ages 20.8-76.4) found statistically significant benefits specifically for memory (standardized mean difference 0.31, Hedges' g 0.30) and processing speed, but found no significant effect on overall composite cognitive function or executive function measures (Xu et al. 2024, Frontiers in Nutrition). GRADE certainty was rated moderate for the memory finding and low for the others — meaning future research could still change these estimates. This study was funded by China's National Natural Science Foundation, a government grant body, with no industry funding disclosed; the paper subsequently received a formal correction in 2025 and has an associated published commentary raising methodological questions, both of which should temper confidence slightly.

A single-dose human trial reported that a large one-time dose of creatine improved specific cognitive performance measures and altered brain high-energy phosphate levels during a period of induced sleep deprivation, consistent with the brain-energy-buffering mechanism, though this remains one trial that needs independent replication.

Working against an overly enthusiastic reading: a 2024 critical review titled "Creatine supplementation research fails to support the theoretical basis for an effect on cognition" directly challenged the mechanistic assumptions behind the cognition claims, arguing the proposed brain-energy pathway is weaker in evidence than proponents suggest. And in November 2024, the European Food Safety Authority's independent NDA Panel formally reviewed an application (filed by AlzChem Trostberg GmbH, a creatine manufacturer) for a health claim that creatine supplementation improves cognitive function, and concluded: "a cause-and-effect relationship has not been established between creatine supplementation and an improvement in cognitive function." The panel noted that positive findings, such as improved response inhibition at 20 g/day for 7 days, were isolated findings among the ten intervention studies reviewed, and judged the proposed mechanistic evidence "weak" (EFSA NDA Panel 2024).

Older-adult strength and sarcopenia prevention

Strong — A 2025 meta-analysis pooling 20 studies and 1,093 older-adult participants (69% female) found that creatine combined with exercise training produced a statistically significant improvement in one-repetition-maximum (1RM) strength (mean difference +2.122 kg, p=0.001) and a significant reduction in body fat percentage (mean difference -0.548%, p=0.026) compared with exercise training alone. There was no significant effect on total-body bone mineral density, which the authors flagged as needing further study (Sharifian et al. 2025, European Review of Aging and Physical Activity). This study declared no funding and no competing interests, and was conducted by academic teams in Iran and the UK.

The practical implication for sarcopenia (age-related muscle loss) prevention is that creatine functions as an adjunct to resistance training, not a replacement for it — the benefit shows up specifically in the creatine-plus-exercise groups compared with exercise-only control groups, not from creatine supplementation alone in sedentary older adults.

Creatine for women: dosing, menstrual cycle, and pregnancy

Moderate — The "creatine for women" trend correcting decades of male-dominated sports-nutrition research is directionally justified, but some of the specific claims circulating outrun the evidence.

A randomized crossover trial of 30 women compared creatine supplementation (4 x 5 g/day for 5 days) against placebo across different menstrual cycle phases and found no significant difference in body mass or fluid distribution (total body water, extracellular fluid, or intracellular fluid) between creatine and placebo, or between cycle phases (Wooding et al. 2023, Nutrients) — directly contradicting a common social-media claim that creatine causes disproportionate water retention or bloating tied to hormonal phase. This trial received no external cash funding, though the creatine monohydrate itself was donated free of charge by AlzChem Trostberg GmbH, an in-kind tie worth disclosing even though the funder had no apparent motive to bias a null water-retention result.

A separate trial in 39 women examined recovery markers across the menstrual cycle with 20 g/day creatine and found no effect on heart rate variability, but did find a phase-by-supplement interaction for a fatigue index (p=0.048), with the greatest improvement occurring in the high-hormone luteal phase — a preliminary signal, not a settled finding, and again carrying the same AlzChem in-kind creatine donation disclosure.

A 2024 narrative review focused specifically on women, vegans, and clinical populations noted that women tend to have roughly 70-80% of the muscle creatine content of men at baseline and consume less dietary creatine on average, theoretically predicting a proportionally larger response to supplementation, though large confirmatory RCTs specifically powered to detect sex-based response differences remain limited (narrative review, Nutrients 2024). This review declared no external funding.

On pregnancy: independent human-trial evidence on creatine supplementation during pregnancy is currently insufficient to support a recommendation either way. Some observational and mechanistic research in pregnancy nutrition has explored creatine's role in fetal energy metabolism, but controlled human supplementation trials in pregnant women are not established well enough for this article to draw a safety or efficacy conclusion. Independent human-trial evidence is insufficient to conclude that creatine supplementation is either beneficial or clearly safe during pregnancy, and pregnant women should not supplement without discussing it with their obstetric care provider.

Loading dose vs. maintenance dose

Strong — Two dosing strategies dominate the literature. The traditional "loading" protocol uses roughly 0.3 g/kg/day (about 20-25 g/day for an average adult) split into 4 doses for 5-7 days, followed by a maintenance dose of 3-5 g/day. The alternative slow-loading protocol simply starts at 3-6 g/day and continues for 3-4 or more weeks. Both protocols raise muscle creatine stores to a similar elevated plateau — the loading protocol just gets there in about a week, while the low-dose protocol takes roughly a month (Buford et al. 2007, ISSN Position Stand).

The practical tradeoff: loading produces faster results (useful before a competition or a short training block) but is more likely to cause the transient gastrointestinal discomfort and water-weight gain some users report in the first week, since more creatine is being absorbed and osmotically retained at once. For someone with no near-term performance deadline, skipping the loading phase and starting at a steady 3-5 g/day is a reasonable, better-tolerated approach that reaches the same destination.

"Non-responders" to creatine

Established phenomenon, moderate mechanistic understanding — Not everyone who supplements with creatine shows the same magnitude of muscle creatine increase or performance benefit. Individual variation in baseline muscle creatine content is the primary driver: people who start with muscle creatine stores already close to the physiological ceiling (commonly seen in some habitual high-meat-eaters or certain muscle fiber-type profiles) have less room to increase further, and tend to show a smaller response. People starting from a lower baseline — often vegetarians, vegans, and those with lower muscle mass — tend to show a larger relative response. This is a legitimate physiological explanation, not evidence that creatine "doesn't work" for a meaningful subset of users; it explains why average effect sizes in meta-analyses represent a mix of large responders and modest responders rather than a uniform effect.

Vegetarians and vegans

Moderate-to-strong, mechanistically well-supported — Because dietary creatine comes almost entirely from animal flesh, vegetarians and vegans typically have lower baseline muscle and possibly brain creatine stores than omnivores. The 2024 narrative review on women, vegans, and clinical populations summarized this baseline difference and the theoretical case for a larger relative response to supplementation in this group, though the review itself declared no external funding and is an academic synthesis rather than a new trial (Nutrients 2024). Some smaller trials in vegetarians have reported larger absolute strength and cognitive-performance gains with supplementation relative to omnivore controls, consistent with a "more room to fill the tank" explanation, though the number of dedicated, adequately powered vegetarian/vegan-specific RCTs remains limited.

Form comparisons: HCl, buffered, and nano vs. monohydrate

Contested claim, resolved against the marketing — This is covered in detail in the forms table above. The short version: an 8-week randomized, double-blind trial directly comparing buffered creatine (Kre-Alkalyn) against monohydrate in 36 resistance-trained participants found no significant difference in muscle creatine content, body composition changes, or training adaptations (Jagim et al. 2012, JISSN). This trial was funded by AlzChem AG, a company that manufactures monohydrate (Creapure) — a funder with a directional interest in this particular null result, which is disclosed here even though the finding is corroborated by independent narrative reviews reaching the same conclusion across forms (Antonio et al. 2021 critical review, itself flagged for an AlzChem-funded article-processing charge).

No independently replicated, adequately powered human trial has shown creatine HCl, ethyl ester, buffered, micronized, or "nano" forms outperforming monohydrate on any hard outcome — muscle creatine saturation, strength, power, or lean mass. Ethyl ester specifically underperformed monohydrate at raising muscle and serum creatine in available pharmacokinetic comparisons, converting more readily to creatinine (a waste product) instead.

Kidney safety in healthy adults (the "creatine damages your kidneys" myth)

Strong evidence against the myth in healthy adults; genuine caution in pre-existing kidney disease — This is the single most persistent creatine myth, and it traces back to a basic biochemistry confusion: creatine supplementation raises blood creatinine (a breakdown product of creatine metabolism, and the standard lab marker used to estimate kidney function), which can make routine bloodwork look like declining kidney function even when the kidneys are functioning normally.

A 2025 systematic review and meta-analysis of 21 studies (12 pooled for meta-analysis, covering 440 total participants) found that creatine supplementation was associated with a small, statistically significant increase in serum creatinine (mean difference 0.07 µmol/L, 95% CI 0.01 to 0.12, p=0.03), but the effect was inconsistent by duration — significant at 1 week or less and again beyond 12 weeks, but not significant in the 1-12 week range — and crucially, there was no significant change in glomerular filtration rate (GFR), the actual functional measure of kidney filtering capacity. The authors concluded the creatinine rise reflects increased metabolic turnover, not renal impairment, and that GFR findings suggest preserved kidney function (Kabiri Naeini et al. 2025, BMC Nephrology). This study, from Isfahan University of Medical Sciences in Iran, declared no funding and no competing interests — a clean independence profile on a topic where funding matters a great deal.

A separate 2025 narrative safety review reached a similar overall conclusion about healthy-adult kidney safety, but two of its four authors disclosed direct financial ties to AlzChem, including research grants, creatine donations, travel support, speaking honoraria, and a Scientific Advisory Board seat for one author, plus research grants and supplement donations from AlzChem and other companies for a second author (Longobardi, Solis, Roschel & Gualano 2025, Frontiers in Nutrition). This paper is used here only as supporting narrative context, cross-checked against the fully independent Kabiri Naeini meta-analysis above, not as a standalone basis for the safety conclusion.

The genuine caution that remains: published case reports exist of kidney injury in individuals taking creatine, but in the cases with enough clinical detail to evaluate, confounding factors were typically present — pre-existing kidney disease, concurrent use of nephrotoxic drugs, or extreme/unsupervised dosing far above standard recommendations. This is a real reason for people with existing kidney disease to seek medical guidance before supplementing, but it is not evidence that standard-dose creatine causes kidney damage in a healthy person with normally functioning kidneys.

Hair loss myth

Weak original claim, contradicted by newer controlled data — The creatine-causes-hair-loss claim originates almost entirely from one 2009 study in college rugby players that found an increase in dihydrotestosterone (DHT, a hormone associated with androgenic hair loss in genetically susceptible people) after a creatine loading and maintenance protocol. That study did not measure actual hair loss or hair follicle outcomes — it measured a hormone level and inferred a hypothetical downstream risk.

A more recent randomized controlled trial revisited this question directly and did not replicate the original DHT-elevation finding under controlled conditions, undermining the sole mechanistic pillar the hair-loss claim has rested on for over a decade. Independent human-trial evidence directly linking standard-dose creatine monohydrate supplementation to measurable hair shedding, thinning, or accelerated androgenic alopecia in a controlled trial does not currently exist. The honest, precise statement is: independent human-trial evidence is insufficient to conclude that creatine supplementation causes hair loss — the claim rests on one hormone-level finding from 2009 that a subsequent controlled trial failed to reproduce.

People with a strong personal or family history of androgenic alopecia who are still concerned can reasonably choose to monitor for changes after starting creatine, but should understand they are acting on a precautionary, unproven hypothesis rather than an established causal risk.

GI tolerability and water retention

Established, dose-dependent, generally mild — Gastrointestinal discomfort (bloating, cramping, diarrhea) is the most commonly reported side effect, and it is clearly dose-dependent: it occurs more frequently during high-dose loading protocols (20+ g/day split into multiple doses) than during steady maintenance dosing (3-5 g/day). Taking creatine with food, splitting doses throughout the day, and ensuring adequate water intake all reduce GI symptoms in practice, consistent with an osmotic mechanism — undissolved or rapidly-ingested creatine drawing water into the gut lumen.

Water retention is real but has been mischaracterized. Early-phase water retention (roughly 1-2 kg of scale-weight increase during the first 1-2 weeks) reflects creatine pulling water into muscle cells intracellularly — this is different from the subcutaneous, "puffy" fluid retention some people fear, and it is not the same as fat gain. The menstrual-cycle trial discussed above found no significant creatine-vs-placebo difference in total body water, extracellular fluid, or intracellular fluid compartments in women, which somewhat complicates the simple "creatine always causes water weight" narrative and suggests the effect may be smaller or more individually variable than commonly assumed (Wooding et al. 2023).

The caffeine interaction debate

Contested, insufficient independent evidence to settle — A long-standing claim holds that caffeine blunts creatine's ergogenic effect, based on a small, older study finding caffeine co-ingestion negated creatine's usual improvement in a specific torque/relaxation measure. This has been debated for years, and subsequent research has produced inconsistent results — several other trials combining creatine and caffeine (including in pre-workout formulations) have found no clear antagonism on strength or power output. The honest conclusion is that independent human-trial evidence has not converged on a clear, replicated mechanism or magnitude of interaction between caffeine and creatine's ergogenic effects; the two are commonly co-ingested in pre-workout products without a well-established performance downside, but the original "avoid combining them" claim is also not solidly disproven across all outcome measures. This is a genuine open question rather than a settled myth in either direction.

Benefits by claim

Risks and all side effects

Creatine monohydrate has one of the largest human safety databases of any sports supplement — narrative safety reviews cite well over 500 published human trials with no consistent signal of serious harm at standard doses in healthy people. That does not mean it is risk-free; it means the known risk profile is unusually well characterized for a supplement.

Independent human-trial evidence does not support hair loss, general "kidney damage" in healthy adults, liver damage in healthy adults at standard doses, or dehydration/heat-illness risk as established side effects — each of these claims is either unreplicated, contradicted by newer data, or lacks a controlled human trial establishing causation at standard doses.

All interactions

Direct, dedicated human interaction trials between creatine and most prescription drug classes are limited — this is a genuine evidence gap, not proof of safety, and is stated plainly rather than glossed over.

Where this article states "no confirmed interaction" or "no direct human interaction trial identified," that reflects the absence of dedicated independent human research on that specific combination — it is a data gap, not a certification of safety. Anyone on prescription medication, particularly for kidney, liver, or cardiovascular conditions, should discuss creatine supplementation with their prescriber before starting.

Who should avoid creatine monohydrate

• People with pre-existing kidney disease — the strongest, most consistent caution in the literature; case reports of kidney injury associated with creatine use disproportionately involve people who already had reduced kidney function.
• People taking nephrotoxic medications (certain antibiotics, some chemotherapy agents, chronic high-dose NSAIDs) — theoretical additive kidney stress makes medical guidance advisable before combining with creatine.
• Pregnant and breastfeeding women — independent human-trial evidence establishing safety or benefit in pregnancy is insufficient; this is an avoid-until-cleared-by-a-clinician situation, not an established-safe use case.
• Children and adolescents — most large RCTs enroll adults; pediatric-specific safety and efficacy data are comparatively limited, so use in minors should be guided by a pediatrician, particularly outside a competitive-sport medical-supervision context.
• People with a personal history of bipolar disorder — some limited, mixed research has examined creatine's mood-related effects, and case-level caution has been raised for mania-related mood destabilization in bipolar disorder specifically; this remains a data-limited area, and anyone with bipolar disorder should consult a psychiatrist before supplementing.
• People with a strong personal/family history of androgenic alopecia who remain risk-averse despite the unreplicated evidence base — a reasonable personal choice to avoid or monitor closely, not a scientifically mandated exclusion.

Dosage and how to take creatine monohydrate

Practical notes drawn from the independent trial base and the ISSN position stand (Buford et al. 2007):

• Consistency matters more than timing — daily dosing (any time of day) maintains elevated muscle stores; there is no strong independent evidence that pre- vs. post-workout timing meaningfully changes outcomes.
• Co-ingesting creatine with a carbohydrate or carbohydrate-protein source can enhance muscle creatine retention via an insulin-mediated uptake mechanism.
• 3-5 g/day is adequate for the vast majority of adults for long-term maintenance; larger individuals (i.e., higher muscle mass) sometimes use up to 5-10 g/day, though evidence supporting doses meaningfully above 5 g/day for most users is thinner.
• Cycling creatine (taking scheduled breaks) is common practice but is not required by the evidence — muscle creatine stores return to baseline over several weeks off supplementation, and there's no demonstrated performance or safety benefit to cycling versus continuous use in the available human trials.
• Plain creatine monohydrate powder mixed in water or a beverage is sufficient; there is no independent evidence that capsules, "nano," or exotic delivery formats improve outcomes over the powder form.

Infographics with full text versions

Infographic 1: Creatine forms — what actually beats monohydrate in human trials

Infographic 2: The kidney-safety myth, mechanism vs. reality

Infographic 3: Loading vs. no-loading — same destination, different speed

Related research

Creatine's cognitive and stress-related mechanisms connect to broader brain-energy and stress-resilience topics covered in the Pure City Research sleep prevention guide and stress, anxiety, and depression prevention guide, particularly for readers interested in the sleep-deprivation cognitive-performance angle discussed above. Creatine's kidney-safety profile is relevant background for readers researching the broader blood pressure prevention guide, since kidney and cardiovascular health are physiologically linked. Readers interested in metabolic and glycemic effects of supplements may also want to review the Pure City Research diabetes prevention guide for context on how creatine's mixed glycemic findings compare with more established glucose-management strategies. For general healthy-aging and muscle-preservation strategies relevant to the older-adult sarcopenia findings above, see the heart disease prevention guide, given the shared emphasis on resistance training and lean mass preservation in cardiometabolic risk reduction.

Frequently asked questions

Sources and funding notes

Animal and non-human evidence excluded

No in-vitro (non-animal) evidence was relied upon to support any claim in this article — sufficient independent human-trial evidence was available for every benefit and safety claim made above, so the in-vitro fallback described in the Pure City Research evidence standard was not invoked.